Nexalin Technology Announces UCSD IRB Approval for use of HALO™ Clarity in Clinical Trials for mTBI and PTSD Treatment

Core Insights - Nexalin Technology, Inc. has received Institutional Review Board (IRB) approval from the University of California, San Diego (UCSD) for clinical testing of its HALO™ Clarity headset in human subjects, marking a significant milestone for the company [1][4] - The independent study at UCSD will evaluate the efficacy of HALO in treating mild traumatic brain injury (mTBI) and post-traumatic stress disorder (PTSD), particularly in military personnel [2][4] Company Overview - Nexalin Technology specializes in Deep Intracranial Frequency Stimulation (DIFS) technology, which provides non-invasive deep-brain stimulation without drugs or invasive procedures [3][7] - The HALO device is designed to be a drug-free alternative for mental health care, reducing the risk of side effects associated with pharmacological treatments [5][7] Clinical Trial Details - UCSD has requested and will receive 50 HALO devices from Nexalin for the independent research project, with the initial shipment already in preparation [2][4] - The clinical trials will utilize a virtual clinic model that incorporates artificial intelligence (AI) and a proprietary Electronic Data Capture (EDC) platform to enhance patient care and ensure real-time monitoring of treatment progress [3][5] Technology and Innovation - The HALO device allows for at-home use, providing comfort and convenience for patients while enabling remote monitoring by physicians [5][6] - The integration of AI facilitates real-time data acquisition and analysis during clinical trials, improving efficiency and compliance [5][6] Future Outlook - The independent study at UCSD aims to provide essential data to further establish HALO as a revolutionary treatment option for mTBI and PTSD, building upon prior research that has shown DIFS technology's ability to modulate neural activity [4][6] - Nexalin remains committed to pioneering neuromodulation technologies to address unmet needs in mental health and neurological care [4][7]